XERS (Xeris Biopharma Holdings) Cash And Cash Equivalents : $58.4 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Cash And Cash Equivalents?

Xeris Biopharma Holdings's quarterly cash and cash equivalents increased from Sep. 2024 ($59.23 Mil) to Dec. 2024 ($71.62 Mil) but then stayed the same from Dec. 2024 ($71.62 Mil) to Mar. 2025 ($58.44 Mil).

Xeris Biopharma Holdings's annual cash and cash equivalents declined from Dec. 2022 ($121.97 Mil) to Dec. 2023 ($67.45 Mil) but then increased from Dec. 2023 ($67.45 Mil) to Dec. 2024 ($71.62 Mil).

Xeris Biopharma Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Xeris Biopharma Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Cash And Cash Equivalents Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

37.60

67.27

121.97

67.45

71.62

Xeris Biopharma Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															62.69	57.60	59.23	71.62	58.44

Xeris Biopharma Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Xeris Biopharma Holdings (NAS:XERS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Xeris Biopharma Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0A8E:UK 2B30:Germany 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Executives

Beth Hecht	officer: See Remarks	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper	officer: Chief Financial Officer	XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff	director	C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr	officer: See Remarks	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Paul R Edick	director, officer: See Remarks	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley	director	XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski	officer: Chief Scientific Officer	C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Marla Persky	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Kenneth Erland Johnson	officer: See Remarks	C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Barbara-jean Anne Bormann-kennedy	director	1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Barry M. Deutsch	officer: See Remarks	OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015